Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Automated Device Safety Surveillance Gets Proof Of Principle

This article was originally published in The Gray Sheet

Executive Summary

Comprehensively tracking post-market safety signals presents an almost insurmountable challenge for the limited staff in FDA's device center. But a new automated computer surveillance system should be able to provide needed assistance, scientists from CDRH, Harvard University and other institutions say.

You may also be interested in...



FDA’s Latest Post-Market Plan: Data-Mining Device Safety

Data-mining software tools will be used by FDA to find troubling patterns with particular devices as part of the agency’s latest plan to beef up its post-market surveillance activities.

FDA’s Latest Post-Market Plan: Data-Mining Device Safety … And Then There’s MAUDE

Data-mining software tools will be used by FDA to find troubling patterns with particular devices as part of the agency’s latest plan to beef up its post-market surveillance activities. However, “we haven’t determined the device areas in which we will implement data-mining,” CDRH Chief Scientist William Maisel said. Meanwhile, a new system will be piloted to replace the MAUDE adverse event database, and CDRH Director Jeffrey Shuren explains why Unique Device Identification and product registries will play an important role in the new post-market plan.

Pilot Programs To Inform Future Studies

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel